TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Jeff P Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.